Geranylgeraniol Supplementation in Patients With Mevalonate Kinase Deficiency
Recruiting
N/A
Interventional Study
Mevalonate Kinase Deficiency
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 12 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 6 (estimated)
- Sponsor
- University Hospital, Motol · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Mevalonate kinase deficiency (HyperIgD syndrome, HIDS) is an inborn error of immunity caused by a block in the mevalonate pathway. The subsequent lack of isoprenoids with antiinflammatory properties might contribute to the autoinflammatory nature of the disease.
A pilot study aims to verify the safety and efficacy of the dietary supplement Geranylgeraniol, aiming at a mitigation of isoprenoids de…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Patients older than 12 years with genetically confirmed MVK deficiency
* Overall good clinical status apart from the clinical presentation of the MVK deficiency
* Normal liver tests
* Compliance with the study protocol
Exclusion Criteria:
• Children below 12 years
Contacts